IP Library › Granted Patent US 7,378,384
Granted Patent B2
US 7,378,384 · App. 10/528,360 · Granted May 27, 2008

WT1 substitution peptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,378,384
App. No.
10/528,360
Granted
May 27, 2008
Kind
B2
Abstract

Novel substituted type peptides of WT1 wherein the cysteine residue is substituted with a defined amino acid residue, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. Peptides which comprise an amino acid sequence of the formula: X-Y-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 4) wherein X represents Ser, Ala, Abu, Arg, Lys, Orn, Cit, Leu, Phe, or Asn, and Y represents Tyr or Met, and which has an activity to induce CTLs, polynucleotides encoding said peptides, cancer vaccines which comprise those peptides or polynucleotides as an active ingredient, and the like are disclosed.

Claims (22)

1. An isolated peptide which comprises the amino acid sequence of the formula:

X-Y-Thr-Trp-Asn-Gln-Met-Asn-Leu

(SEQ ID NO: 4)

wherein

X represents Ala, Abu, Arg, Lys, Orn, Cit, Leu, Phe or Asn,

Y represents Tyr or Met, and

the peptide induces cytotoxic T lymphocytes (CTLs).

2. The peptide according to claim 1 , which comprises

Ala-Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 6),

Abu-Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 7),

Arg-Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 8),

Lys-Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 9),

Orn-Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 10),

Cit-Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 11),

Leu-Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 12),

Phe-Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 13),

Asn-Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 14), or

Ala-Met-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 16).

3. The peptide according to claim 1 , which consists of any one of the amino acid sequences selected from a group consisting of SEQ ID NOs: 6, 7, 8, 9, 10, 11, 12, 13, 14 and 16.

4. A pharmaceutical composition for inducing CTLs, which comprises the peptide according to claim 1 and a pharmaceutically acceptable carrier.

5. A pharmaceutical composition for inducing CTLs, which comprises the peptide according to claim 2 and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition for inducing CTLs, which comprises the peptide according to claim 3 and a pharmaceutically acceptable carrier.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2017
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Reel/Frame 043305/0542 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2016
From: CHUGAI SEIYAKU KABUSHIKI KAISHA
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 038364/0495 →
CHANGE OF NAME Recorded Oct 10, 2014
From: DAINIPPON SUMITOMO PHARMA CO., LTD.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 033969/0194 →
CORRECTED FORM PTO-1595 CORRECT ASSIGNEES #2 AND # Recorded Dec 13, 2006
From: SUGIYAMA, HARUO; GOTOH, MASASHI; TAKASU, HIDEO; SAMIZO, FUMIO; KUSUNOSE, NAOTO; NAKATSUKA, MASASHI
To: SUGIYAMA, HARUO; CHUGAI SEIYAKU KABUSHIKI KAISHA; SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
Reel/Frame 018704/0620 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2006
From: SUGIYAMA, HARUO
To: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Reel/Frame 018192/0210 →
MERGER Recorded Dec 28, 2005
From: SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
To: DAINIPPON SUMITOMO PHARMA CO., LTD.
Reel/Frame 017149/0949 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2005
From: SUGIYAMA, HARUO; GOTOH, MASASHI; TAKASU, HIDEO; SAMIZO, FUMIO; KUSUNOSE, NAOTO; NAKATSUKA, MASASHI
To: SUGIYAMA, HARUO; CHUGAI SEIYAKU KABUSHIKI KAISHA; SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
Reel/Frame 016836/0856 →